Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

A joint research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Science at the University of Hong Kong has uncovered an unexpected interaction between chemotherapeutic agents and a ...

WAYNE, Penn.--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the launch of its newest ...

At present, this disease is considered to represent a specific immunological response of the colonic mucosa to various noxious luminal agents in predisposed individuals. Some cases are associated ...

9,10 Luminal stimuli, such as bitter tastants ... 77 However, the cosmetic use of these agents by celebrities, athletes, and, most concerning, adolescents without a medical indication could ...

Cagent Vascular, Inc. announced the launch of its Serranator SL-Pro percutaneous transluminal angioplasty (PTA) serration ballo ...

Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation ... in clinical trials undertaken in patients with IBD, and these agents have led to a ...

Of note, AKT seems to represent a transversal target across the BC intrinsic subtypes (i.e., luminal HER2-, HER2 enriched ... immunotherapeutic agents or PARP-inhibitors and the results from these ...

Coronary microvascular disease may reflect anatomical abnormalities including microvascular remodelling (ie, reductions in capillary luminal size ... tests of coronary artery function, therapeutic ...

Operator, a new computer-using tool from OpenAI, is brittle and occasionally erratic, but it points to a future of powerful A.I. agents. Credit...Ard Su Supported by By Kevin Roose Reporting from ...